نتائج البحث

HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.

• Authors : Wen, X.-F.¹; Yang, G.²; Mao, W.¹

• Source: Oncogene. 11/2/2006, Vol. 25 Issue 52, p6986-6996. 11p. 6 Graphs.

تفاصيل العنوان

OVERVIEW OF MONOCLONAL ANTIBODY THERAPY.

• Authors : Goodin, Susan

• Source: American Journal of Health-System Pharmacy. Jul2006 Supplement, Vol. 63, p4-7. 4p.

تفاصيل العنوان

Non-Hodgkin's Lymphomas: Understanding Monoclonal Antibody Therapy.

• Authors : Hendrix, Carolyn

• Source: ONS News. Aug2006 Supplement, Vol. 21, p19-20. 2p.

تفاصيل العنوان

Violent Reaction to Monoclonal Antibody Therapy Remains a Mystery.

• Authors : Marshall, Eliot; Vogel, Gretchen¹

• Source: Science. 3/24/2006, Vol. 311 Issue 5768, p1688-1689. 2p. 1 Color Photograph, 1 Diagram.

تفاصيل العنوان

Overview of monoclonal antibody therapy.

• Authors : Goodin S (AUTHOR)

• Source: American Journal of Health-System Pharmacy. Jul2006 Supplement, Vol. 63, p4-7. 4p.

تفاصيل العنوان

Fc gamma receptors and cancer.

• Authors : Cassard, Lydie^1,2; Cohen-Solal, Joël^1,3; Camilleri-Broët, Sophie^1,4

• Source: Springer Seminars in Immunopathology. Dec2006, Vol. 28 Issue 4, p321-328. 8p.

تفاصيل العنوان

A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study.

• Authors : Rech, Juergen¹ (AUTHOR) ; Repp, Roland² (AUTHOR); Rech, Dorit¹ (AUTHOR)

• Source: Leukemia & Lymphoma. Oct2006, Vol. 47 Issue 10, p2147-2154. 8p. 4 Charts, 2 Graphs.

تفاصيل العنوان

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.

• Authors : Juliusson, G.¹ ; Theorin, N.²; Karlsson, K.¹

• Source: Bone Marrow Transplantation. Mar2006, Vol. 37 Issue 5, p503-510. 8p. 6 Charts, 3 Graphs.

تفاصيل العنوان

Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed.

• Authors : Belgi, A. S.¹; Azeez, M.¹; Hoyle, C.²

• Source: Clinical & Experimental Dermatology. Jan2006, Vol. 31 Issue 1, p143-143. 1p.

تفاصيل العنوان

Antibody therapy phase I trial safety remains topical.

• Source: Reactions Weekly. 9/30/2006, Issue 1121, p4-4. 1/4p.

تفاصيل العنوان